Analyst upgrades: MON, AZN and MLNM
Posted Mar 13th 2008 11:26AM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades
.gif)
MOST NOTEWORTHY: Monsanto, AstraZeneca and Millenium Pharmaceutical were today's noteworthy upgrades:
- Banc of America upgraded shares of Monsanto (NYSE: MON) to Buy from Neutral as they have grown more comfortable with two previous concerns: competition and valuation. They see an attractive entry point ahead of strong expected results for Q2.
- UBS upgraded shares of AstraZeneca (NYSE: AZN) to Neutral from Sell on valuation, as they believe many of the risks are priced into shares at current levels.
- Piper upgraded Millenium Pharma (NASDAQ: MLNM) to Buy from Neutral and added shares to their Alpha List ahead of additional front-line Velcade presentations at ASCO and expected front-line Velcade approval by June 20.
OTHER UPGRADES:
Tags: analyst, astrazeneca, azn, gsi commerce, gsic, GsiCommerce, ja solar, jaso, JaSolar, millenium, mlnm, mon, monsanto, upgrade, wbd, wimm-bill-dann
So long peak oil, here comes peak uranium
Black Friday expected to be strong, no promises for Christmas
Will JPMorgan chief Jamie Dimon be our next Treasury Secretary?
